| abstract |
The present invention relates to a proapolipoprotein A-1 variant and an agent for preventing and treating hyperlipidemia or atherosclerosis comprising the same, and more specifically, Arg-His-Phe-Trp at the amino acid terminal of apolipoprotein (apoA-I). Variant of proapo AI containing a mutation at position 154, 155, 156, 157 or 158 of apo AI in a proapoprotein comprising -Gln-Gln, a nucleic acid encoding said variant The present invention relates to a recombinant vector comprising the nucleic acid, a transformant transfected with the vector, and a hyperlipidemia or arteriosclerosis prevention and treatment agent containing the variant as an active ingredient. |